Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01048554 · ClinicalTrials.gov registry record · Phase 2
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
A Phase 2 study, sponsored by Mt. Sinai Medical Center, Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01048554 is a Phase 2 study that has completed, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 34 participants.
The verdict
NCT01048554, a Phase 2 study, has completed, sponsored by Mt. Sinai Medical Center, Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This research is being done because melanoma in the brain is very difficult to treat because it does not respond to radiation or to chemotherapy, such as temozolomide. One of the reasons for this is that the melanoma can make chemicals that signal the brain to provide new blood vessels for the tumor. The main signal is called VEGF. Bevacizumab is an antibody that blocks VEGF. The investigators want to see if the combination of bevacizumab and temozolomide will stop the melanoma from growing.
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01048554
The ClinicalTrials.gov registry entry for NCT01048554 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mt. Sinai Medical Center, Miami, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01048554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01048554 about?
NCT01048554 is a clinical study titled "Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System". This research is being done because melanoma in the brain is very difficult to treat because it does not respond to radiation or to chemotherapy, such as temozolomide. One of the reasons for this is that the melanoma can make chemicals that signal the brain to provide new blood vessels for the tumor...
What is the current status of trial NCT01048554?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2009-11. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01048554?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT01048554?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.